中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌靶向/免疫治疗效果的预测指标

任鹏伟 韩英 周新民

引用本文:
Citation:

肝细胞癌靶向/免疫治疗效果的预测指标

DOI: 10.3969/j.issn.1001-5256.2023.11.028
基金项目: 

国家自然科学基金 (81870421)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:任鹏伟负责撰写论文;韩英负责修改论文;周新民负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    周新民, zhouxmm@fmmu.edu.cn (ORCID: 0000-0002-6521-9885)

Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma

Research funding: 

National Natural Science Foundation of China (81870421)

More Information
  • 摘要: 肝细胞癌(HCC)是我国常见恶性肿瘤,用于晚期HCC治疗的分子靶向药物和免疫检查点抑制剂是当下的研究热点,但治疗效果存在较大的个体差异。为进一步筛选获益人群,预测治疗效果,改善疾病预后,本文对HCC靶向/免疫治疗的效果预测相关研究进行总结,为晚期HCC患者制订个体化的治疗方案提供参考。

     

  • [1] ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394( 10204): 1145- 1158. DOI: 10.1016/S0140-6736(19)30427-1.
    [2] RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [3] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [4] LI SS, GUO ZT, CHEN ZB, et al. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37( 12): 2943- 2946. DOI: 10.3969/j.issn.1001-5256.2021.12.044.

    李世思, 郭志唐, 陈章彬, 等. 晚期肝细胞癌系统治疗的研究进展[J]. 临床肝胆病杂志, 2021, 37( 12): 2943- 2946. DOI: 10.3969/j.issn.1001-5256.2021.12.044.
    [5] KUZUYA T, ISHIGAMI M, ITO T, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment[J]. Hepatol Res, 2019, 49( 9): 1054- 1065. DOI: 10.1111/hepr.13358.
    [6] HERSBERGER L, BARGETZI L, BARGETZI A, et al. Nutritional risk screening(NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial[J]. Clin Nutr, 2020, 39( 9): 2720- 2729. DOI: 10.1016/j.clnu.2019.11.041.
    [7] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
    [8] KIM B, KIM SS, CHO SW, et al. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma[J]. Eur Radiol, 2021, 31( 4): 2507- 2517. DOI: 10.1007/s00330-020-07357-9.
    [9] NICOLAS-BOLUDA A, VAQUERO J, VIMEUX L, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment[J]. Elife, 2021, 10: e58688. DOI: 10.7554/eLife.58688.
    [10] YUAN G, XIE F, SONG Y, et al. Hepatic tumor stiffness measured by shear wave elastography is prognostic for HCC progression following treatment with anti-PD-1 antibodies plus lenvatinib: A retrospective analysis of two independent cohorts[J]. Front Immunol, 2022, 13: 868809. DOI: 10.3389/fimmu.2022.868809.
    [11] WANG F, QIN S, SUN X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13( 1): 47. DOI: 10.1186/s13045-020-00886-2.
    [12] DÍAZ-GONZÁLEZ Á, SANDUZZI-ZAMPARELLI M, SAPENA V, et al. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib[J]. Aliment Pharmacol Ther, 2019, 49( 5): 482- 491. DOI: 10.1111/apt.15088.
    [13] MAO J, WANG D, LONG J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9( 12): e003334. DOI: 10.1136/jitc-2021-003334.
    [14] DAVID LA, MAURICE CF, CARMODY RN, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505( 7484): 559- 563. DOI: 10.1038/nature12820.
    [15] GALLE PR, FOERSTER F, KUDO M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39( 12): 2214- 2229. DOI: 10.1111/liv.14223.
    [16] SHAO YY, LIU TH, HSU C, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Liver Int, 2019, 39( 11): 2184- 2189. DOI: 10.1111/liv.14210.
    [17] ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20( 2): 282- 296. DOI: 10.1016/S1470-2045(18)30937-9.
    [18] AO H, XIN Z, JIAN Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma[J]. Biomark Res, 2021, 9( 1): 91. DOI: 10.1186/s40364-021-00348-y.
    [19] YUE C, JIANG Y, LI P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7( 7): e1438111. DOI: 10.1080/2162402X.2018.1438111.
    [20] WINOGRAD P, HOU S, COURT CM, et al. Hepatocellular carcinoma-circulating tumor cells expressing PD-L1 are prognostic and potentially associated with response to checkpoint inhibitors[J]. Hepatol Commun, 2020, 4( 10): 1527- 1540. DOI: 10.1002/hep4.1577.
    [21] SCHEINER B, POMEJ K, KIRSTEIN MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy-development and validation of the CRAFITY score[J]. J Hepatol, 2022, 76( 2): 353- 363. DOI: 10.1016/j.jhep.2021.09.035.
    [22] YOSHIDA T, ICHIKAWA J, GIUROIU I, et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma[J]. J Immunother Cancer, 2020, 8( 1): e000234. DOI: 10.1136/jitc-2019-000234.
    [23] JIMENEZ RV, KUZNETSOVA V, CONNELLY AN, et al. C-reactive protein promotes the expansion of myeloid derived cells with suppressor functions[J]. Front Immunol, 2019, 10: 2183. DOI: 10.3389/fimmu.2019.02183.
    [24] AKAMINE T, TAKADA K, TOYOKAWA G, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers[J]. Surg Oncol, 2018, 27( 1): 88- 94. DOI: 10.1016/j.suronc.2018.01.002.
    [25] BRUIX J, CHENG AL, MEINHARDT G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies[J]. J Hepatol, 2017, 67( 5): 999- 1008. DOI: 10.1016/j.jhep.2017.06.026.
    [26] MEI J, SUN XQ, LIN WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy[J]. J Inflamm Res, 2021, 14: 3879- 3890. DOI: 10.2147/JIR.S325600.
    [27] DHARMAPURI S, ÖZBEK U, LIN JY, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy[J]. Cancer Med, 2020, 9( 14): 4962- 4970. DOI: 10.1002/cam4.3135.
    [28] HARDING JJ, NANDAKUMAR S, ARMENIA J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25( 7): 2116- 2126. DOI: 10.1158/1078-0432.CCR-18-2293.
    [29] MASUDA M, CHEN WY, MIYANAGA A, et al. Alternative mammalian target of rapamycin(mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling[J]. Mol Cell Proteomics, 2014, 13( 6): 1429- 1438. DOI: 10.1074/mcp.M113.033845.
    [30] LLOVET JM, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15( 10): 599- 616. DOI: 10.1038/s41571-018-0073-4.
    [31] SCHULZE K, IMBEAUD S, LETOUZÉ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47( 5): 505- 511. DOI: 10.1038/ng.3252.
    [32] PINYOL R, SIA D, LLOVET JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC[J]. Clin Cancer Res, 2019, 25( 7): 2021- 2023. DOI: 10.1158/1078-0432.CCR-18-3778.
    [33] SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153( 3): 812- 826. DOI: 10.1053/j.gastro.2017.06.007.
    [34] LIU CQ, XU J, ZHOU ZG, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma[J]. Br J Cancer, 2018, 119( 1): 80- 88. DOI: 10.1038/s41416-018-0144-4.
    [35] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389( 10088): 2492- 2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [36] YAU T, PARK JW, FINN RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23( 1): 77- 90. DOI: 10.1016/S1470-2045(21)00604-5.
  • 加载中
计量
  • 文章访问数:  147
  • HTML全文浏览量:  40
  • PDF下载量:  32
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-01-16
  • 录用日期:  2023-06-09
  • 出版日期:  2023-11-28
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回